A Safety and Efficacy Study of Hymecromone Tablets for the Treatment of Patients With COVID-19.

NCT ID: NCT05386420

Last Updated: 2022-06-09

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 304 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-05-23
• Study Completion Date: 2022-11-15

Brief Summary

The coronavirus (SARS-CoV-2) is a new strain of coronavirus found in human in 2019, which causes epidemic worldwide. A study found that the increase in hyaluronic acid levels is closely related to the clinical symptoms of COVID-19, including pulmonary ground glass lesions, lymphocytopenia, immune response and cytokine storms, systemic vascular diseases, thrombotic coagulation disorders, which suggests that hyaluronic acid could be an important target for COVID-19 treatment and could improve the clinical symptoms of COVID-19 patients.

The results from a recent clinical trial recruited 144 patients with COVID-19 show that the inhibitor of hyaluronic acid synthesis, hymecromone, can significantly improve clinical symptoms, such as lung lesions and lymphocytopenia in COVID-19 patients. Therefore, hymecromone has the potential to become one of the options of COVID-19 treatment.

This study is a single-center, randomized, parallel controlled, double-blind clinical trial designed to evaluate the efficacy and safety of Hymecromone tablets in subjects aged 18-90 years (with boundary values) with a confirmed mild or moderate form of COVID-19 infection. The aim of this study is to optimize the program of the combination of hymecromone in the treatment of COVID-19 to improve the therapeutic effect.

Conditions

COVID-19

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: DOUBLE

Study Groups

Experimental group

Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.

Group Type: EXPERIMENTAL

Hymecromone tablets

Intervention Type: DRUG

Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.

Control group

Conventional treatment combined with placebo.

Group Type: PLACEBO_COMPARATOR

Placebo

Intervention Type: OTHER

Conventional treatment combined with Placebo.

Interventions

Hymecromone tablets

Conventional treatment combined with Hymecromone tablets, 0.4g , tid ac, 7 days.

Intervention Type: DRUG

Placebo

Conventional treatment combined with Placebo.

Intervention Type: OTHER

Eligibility Criteria

Inclusion Criteria

1. Participants who have a positive SARS-CoV-2 test result ;

2. Participants who have been diagnosed with mild or ordinary type of COVID-19 infection;

3. Participants whose serum hyaluronic acid level was higher than the upper limit of normal value;

4. Participants who must agree to adhere to contraception restrictions;

5. Participants who understand and agree to comply with planned study procedures;

6. Participants who give signed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.

Exclusion Criteria

1. Participants who have any of the following conditions when screening:

1. ALT or AST > 5 ULN;

2. Scr > 1.5 ULN or Ccr < 50 mL/min;

3. TBIL > 2ULN ;

4. HGB ≤ 90 g/ L;

5. PLT ≤ 75×10^9/ L;

2. Participants who have suspected/active infections during the screening period including uncontrolled active bacterial, viral or fungal infections that require systemic treatment, except COVID-19 virus infections;

3. Participants who have any active autoimmune diseases during the screening period and need to be treated with immunosuppressants, including biological agents;

4. Participants who have a medical history of organ transplantation, or plan for organ transplantation including liver transplantation;

5. Participants who need a loading dose of anti-platelet drugs, such as aspirin (>300 mg/day) and clopidogrel (>300 mg/day);

6. Participants who have a medical history of central nervous system and digestive system bleeding, or a tendency of gastrointestinal bleeding, local active ulcer lesions included, in the last three months;

7. Participants who have biliary obstruction;

8. Female participants who are pregnant or breast-feeding or plan to be pregnant within this study period;

9. Male participants whose wife or partner plan to be pregnant within this study period.

10. Participants who have taken the drugs containing coumarin compounds, such as warfarin, within 3 days before screening;

11. Participants who have other diseases requiring hospitalization and/or in a need of surgical treatment within 7 days before screening, or have suffered from life-threatening diseases within 30 days before screening;

12. Participants who have known allergies to any of the components used in the formulation of the interventions;

13. Participants who have taken a part in a clinical study of an investigational intervention in the last 28 days. After 5 half-lives or 28 days, whichever is longer, can be allowed for screening;

14. Participants who are not suitable for this trial, and with any medical condition will compromise their own safety.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Shanghai Zhongshan Hospital

OTHER

Sponsor Role: lead

Responsible Party

Hao Fang

Chief physician, Vice President

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Hao Fang

Role: PRINCIPAL_INVESTIGATOR

Zhong Shan Hospital affiliated to Fudan University

Locations

Zhong Shan Hospital affiliated to Fudan University

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Hao Fang

Role: CONTACT

fang.hao@zs-hospital.sh.cn

+86 21-64041990

Facility Contacts

Hao Fang, M.D.

Role: primary

References

Yang S, Ling Y, Zhao F, Li W, Song Z, Wang L, Li Q, Liu M, Tong Y, Chen L, Ru D, Zhang T, Zhou K, Zhang B, Xu P, Yang Z, Li W, Song Y, Xu J, Zhu T, Shan F, Yu W, Lu H. Hymecromone: a clinical prescription hyaluronan inhibitor for efficiently blocking COVID-19 progression. Signal Transduct Target Ther. 2022 Mar 18;7(1):91. doi: 10.1038/s41392-022-00952-w.

Reference Type: BACKGROUND

PMID: 35304437 (View on PubMed)

Li W, Yang S, Xu P, Zhang D, Tong Y, Chen L, Jia B, Li A, Lian C, Ru D, Zhang B, Liu M, Chen C, Fu W, Yuan S, Gu C, Wang L, Li W, Liang Y, Yang Z, Ren X, Wang S, Zhang X, Song Y, Xie Y, Lu H, Xu J, Wang H, Yu W. SARS-CoV-2 RNA elements share human sequence identity and upregulate hyaluronan via NamiRNA-enhancer network. EBioMedicine. 2022 Feb;76:103861. doi: 10.1016/j.ebiom.2022.103861. Epub 2022 Feb 3.

Reference Type: BACKGROUND

PMID: 35124429 (View on PubMed)

Nagy N, Kuipers HF, Frymoyer AR, Ishak HD, Bollyky JB, Wight TN, Bollyky PL. 4-methylumbelliferone treatment and hyaluronan inhibition as a therapeutic strategy in inflammation, autoimmunity, and cancer. Front Immunol. 2015 Mar 23;6:123. doi: 10.3389/fimmu.2015.00123. eCollection 2015.

Reference Type: BACKGROUND

PMID: 25852691 (View on PubMed)

Salman L, Martinez L, Faddoul G, Manning C, Ali K, Salman M, Vazquez-Padron R. Hyaluronan Inhibition as a Therapeutic Target for Diabetic Kidney Disease: What Is Next? Kidney360. 2023 Jun 1;4(6):e851-e860. doi: 10.34067/KID.0000000000000126. Epub 2023 Apr 14.

Reference Type: DERIVED

PMID: 37055910 (View on PubMed)

Other Identifiers

QJXDS-22-01

Identifier Type: -

Identifier Source: org_study_id